https://www.selleckchem.com/pr....oducts/sodium-l-asco
While for adjuvant imatinib of over 12months, both groups A and B had significantly more favorable RFS than group C, and no significant difference in RFS was found between group A and B. Delayed postoperative adjuvant imatinib for over 4months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treatment with shorter delay has best results. Delayed postoperative adjuvant imatinib for over 4 months in patients with high risk of recurrence of GIST may lead to worse RFS, and longer treat
Me gusta
Comentario
Compartir
